Mucosal vaccination with a multicomponent adenovirus-vectored vaccine protects against Streptococcus pneumoniae infection in the lung

FEMS Immunology and Medical Microbiology

Volumn 55, Issue 3, 2009, Pages 346-351

  Arévalo, Maria T ^a   Xu, Qingfu ^a   Paton, James C ^b   Hollingshead, Susan K ^c   Pichichero, Michael E ^a   Briles, David E ^c   Girgis, Natasha ^a   Zeng, Mingtao ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c University of Alabama at Birmingham   (United States)

Author keywords

Mucosal vaccination; Pneumococcal vaccine; Protective immunity; Replication defective adenovirus; Streptococcus pneumoniae

Indexed keywords

ADENOVIRUS VECTOR; BACTERIAL PROTEIN; IMMUNOGLOBULIN G; MEMBRANE ANTIGEN; N FRAGMENT OF PNEUMOCOCCAL SURFACE PROTEIN A; PNEUMOCOCCAL SURFACE ANTIGEN A; PNEUMOCOCCUS VACCINE; PNEUMOLYSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; LUNG INFECTION; MOUSE; NONHUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ADENOVIRIDAE; ADHESINS, BACTERIAL; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; FEMALE; GENETIC VECTORS; IMMUNOGLOBULIN G; LIPOPROTEINS; LUNG; MICE; MICE, INBRED BALB C; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; STREPTOLYSINS; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 62149092818     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2008.00518.x     Document Type: Article

References (32)

1. Alexander JE, Lock RA, Peeters CC et al 1994) Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun 62 : 5683 5688.
2. Benton KA, Paton JC Briles DE (1997) Differences in virulence for mice among Streptococcus pneumoniae strains of capsular types 2, 3, 4, 5, and 6 are not attributable to differences in pneumolysin production. Infect Immun 65 : 1237 1244.
3. Berry AM Paton JC (1996) Sequence heterogeneity of PsaA, a 37-kilodalton putative adhesin essential for virulence of Streptococcus pneumoniae. Infect Immun 64 : 5255 5262.
4. Bett AJ, Krougliak V Graham FL (1995) DNA sequence of the deletion/insertion in early region 3 of Ad5 dl309. Virus Res 39 : 75 82.
5. Boyer JL, Kobinger G, Wilson JM Crystal RG (2005) Adenovirus-based genetic vaccines for biodefense. Hum Gene Ther 16 : 157 168.
6. Briles DE, Ades E, Paton JC et al 2000a) Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect Immun 68 : 796 800.
7. Briles DE, Hollingshead S, Brooks-Walter A et al 2000b) The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection. Vaccine 18 : 1707 1711.
8. Briles DE, Hollingshead SK, King J et al 2000c) Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis 182 : 1694 1701.
9. Briles DE, Hollingshead SK, Nabors GS, Paton JC Brooks-Walter A (2000d) The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae. Vaccine 19 (suppl 1) : S87 S95.
10. Briles DE, Hollingshead SK, Paton JC et al 2003) Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J Infect Dis 188 : 339 348.
11. Danthinne X Imperiale MJ (2000) Production of first generation adenovirus vectors: a review. Gene Ther 7 : 1707 1714.
12. FDA (2001) Guidance for human somatic cell therapy and gene therapy. Hum Gene Ther 12 : 303 314.
13. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW Vogelstein B (1998) A simplified system for generating recombinant adenoviruses. P Natl Acad Sci USA 95 : 2509 2514.
14. McConnell MJ Imperiale MJ (2004) Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther 15 : 1022 1033.
15. McCullers JA Tuomanen EI (2001) Molecular pathogenesis of pneumococcal pneumonia. Front Biosci 6 : D877 D889.
16. Miyaji EN, Dias WO, Gamberini M et al 2001) PsaA (pneumococcal surface adhesin A) and PspA (pneumococcal surface protein A) DNA vaccines induce humoral and cellular immune responses against Streptococcus pneumoniae. Vaccine 20 : 805 812.
17. Ng P, Parks RJ, Cummings DT, Evelegh CM, Sankar U Graham FL (1999) A high-efficiency Cre/loxP-based system for construction of adenoviral vectors. Hum Gene Ther 10 : 2667 2672.
18. Ogunniyi AD, Folland RL, Briles DE, Hollingshead SK Paton JC (2000) Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect Immun 68 : 3028 3033.
19. Ogunniyi AD, Grabowicz M, Briles DE, Cook J Paton JC (2007) Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect Immun 75 : 350 357.
20. Paton JC (1998) Novel pneumococcal surface proteins: role in virulence and vaccine potential. Trends Microbiol 6 : 85 87 discussion 7-8.
21. Paton JC, Lock RA, Lee CJ et al 1991) Purification and immunogenicity of genetically obtained pneumolysin toxoids and their conjugation to Streptococcus pneumoniae type 19F polysaccharide. Infect Immun 59 : 2297 2304.
22. Pichichero ME Casey JR (2007) Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA 298 : 1772 1778.
23. Randrianarison-Jewtoukoff V Perricaudet M (1995) Recombinant adenoviruses as vaccines. Biologicals 23 : 145 157.
24. Ren B, Szalai AJ, Hollingshead SK Briles DE (2004) Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect Immun 72 : 114 122.
25. Shi Z, Zeng M, Yang G et al 2001) Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines. J Virol 75 : 11474 11482.
26. Singleton RJ, Hennessy TW, Bulkow LR et al 2007) Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297 : 1784 1792.
27. Wu HY, Nahm MH, Guo Y, Russell MW Briles DE (1997a) Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis 175 : 839 846.
28. Wu HY, Virolainen A, Mathews B, King J, Russell MW Briles DE (1997b) Establishment of a Streptococcus pneumoniae nasopharyngeal colonization model in adult mice. Microb Pathogenesis 23 : 127 137.
29. Xu Q, Arevalo MT, Pichichero ME Zeng M (2006) A new complementing cell line for replication-incompetent E1-deleted adenovirus propagation. Cytotechnology 51 : 133 140.
30. Zeng M, Smith SK, Siegel F et al 2001) AdEasy system made easier by selecting the viral backbone plasmid preceding homologous recombination. Biotechniques 31 : 260 262.
31. Zeng M, Xu Q, Hesek ED Pichichero ME (2006) N-fragment of edema factor as a candidate antigen for immunization against anthrax. Vaccine 24 : 662 670.
32. Zeng M, Xu Q, Elias M, Pichichero ME, Simpson LL Smith LA (2007) Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine. Vaccine 25 : 7540 7548.